Chapter 13. Denileukin Diftitox in Novel Cancer Therapy

  1. Arsénio M. Fialho3 and
  2. Ananda M. Chakrabarty4
  1. Lin-Chi Chen1 and
  2. Nam H. Dang2

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch13

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Chen, L.-C. and Dang, N. H. (2010) Denileukin Diftitox in Novel Cancer Therapy, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch13

Editor Information

  1. 3

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 4

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. 1

    Department of Medical Oncology, Nevada Cancer Institute, Las Vegas, NV, USA

  2. 2

    Division of Hematology/Oncology, University of Florida Cancer Center Clinical Trials Office, University of Florida, Gainesville, FL, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528



  • denileukin diftitox in novel cancer therapy;
  • activity in T cell lymphoid malignancies and T cell-mediated phenomena;
  • Denileukin diftitox, potential effectiveness in other tumor types and solid tumors


This chapter contains sections titled:

  • Denileukin Diftitox: Structure and Biology

  • Mechanism of Action

  • Activity in T Cell Lymphoid Malignancies and T Cell-Mediated Phenomena

  • CTCL

  • Other Diseases

  • Conclusion

  • References